Graham Capital Management, L.P. Editas Medicine, Inc. Transaction History

Graham Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $328,476 - $517,245	46,725 Added 303.78%	62,106 $460,000
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $106,093 - $188,592	-16,975 Reduced 52.46%	15,381 $155,000
Q3 2023 Nov 22, 2023	SELL	$6.92 - $9.31 $5,065 - $6,814	-732 Reduced 2.21%	32,356 $252,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $210,439 - $379,519	33,088 New	33,088 $272,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $171,528 - $273,938	14,106 Added 9.79%	158,186 $1.94 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $1.44 Million - $3.08 Million	144,080 New	144,080 $1.7 Million
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $175,000 - $343,413	-12,429 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $329,989 - $504,244	12,429 New	12,429 $329,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.